GPX3 activates autophagy to protect cochlear spiral ganglion neurons from injury in age-related hearing loss

分享:

简介:

  • 作者: Miaomiao An, Huan Yin, Yanan Li, Huan Cao, Zhidong Zhang, Jianwang Yang, Jiantao Wang, Tao Liu, Lei Zhao, Chen Wang, Ruoxiang Miao, Baoshan Wang
  • 杂志: Free Radical Biology and Medicine
  • Doi: https://www.doi.org/10.1016/j.freeradbiomed.2026.03.048
  • 出版日期: 2026/3/16

论文中使用的产品/服务

询价

摘要

Age-related hearing loss (ARHL) represents the most common sensory disorder among the elderly population. Degeneration of spiral ganglion neurons (SGNs) is a key pathological feature of ARHL; however, the underlying mechanisms remain inadequately elucidated. Glutathione peroxidase 3 (GPX3), a vital component of the body's antioxidant system, is integral to maintaining cellular redox homeostasis and promoting cell survival. Nevertheless, its involvement in the pathogenesis and progression of ARHL has not been sufficiently explored. Our study suggested that GPX3 expression in SGNs was significantly decreased, accompanied by increased oxidative stress and apoptosis with aging. Meanwhile, autophagy levels were downregulated in SGNs with increased age. Targeted upregulation of GPX3 in SGNs markedly reduced the hearing threshold, improved wave I amplitude, and alleviated oxidative stress and apoptosis in SGNs. Interestingly, overexpression of GPX3 also led to a significant upregulation in autophagy levels. However, the protective effect of GPX3 was reversed by the autophagy inhibitor. These findings were also confirmed in vitro experiments. Collectively, our results indicated that GPX3 could mitigate apoptosis and oxidative stress in SGNs by activating autophagy, thereby alleviating hearing loss in ARHL mice. Furthermore, we discovered that the small molecule drug ebselen could reduce degeneration and damage in SGNs and effectively enhance auditory function by activating autophagy in both in vivo and in vitro settings. These results offer novel targets and therapeutic strategies for the prevention and treatment of ARHL.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*